Below is a reconciliation of Gilead's GAAP operating results and diluted per share amounts as reported in the press release dated July 17, 2008. Non-GAAP net income and net income per diluted share for the 2008 periods are presented excluding the after-tax impact of the purchased in-process research and development expense incurred in connection with the acquisition of all of Navitas Assets, LLC’s assets related to its cicletanine business, as well as the after-tax impact of stock-based compensation expense and the related methodology for computing dilutive securities for net income per diluted share purposes. Non-GAAP net income and net income per diluted share for the 2007 periods are presented excluding the after-tax impact of stock-based compensation expense and the related methodology for computing dilutive securities for net income per diluted share purposes. Non-GAAP R&D expenses and SG&A expenses for the 2008 and 2007 periods are presented excluding the impact of stock-based compensation expense. Management believes this non-GAAP information is useful for investors, taken in conjunction with Gilead’s GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under GAAP.

<table>
<thead>
<tr>
<th></th>
<th>Three Months Ended</th>
<th>Six Months Ended</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>June 30,</td>
<td>June 30,</td>
</tr>
<tr>
<td>Net income (GAAP)</td>
<td>$ 442,828</td>
<td>$ 407,930</td>
</tr>
<tr>
<td>Stock-based compensation expense, net of tax</td>
<td>26,409</td>
<td>34,260</td>
</tr>
<tr>
<td>Purchased in-process research and development expense, net of tax</td>
<td>7,769</td>
<td>-</td>
</tr>
<tr>
<td>Net income (Non-GAAP)</td>
<td>$ 477,006</td>
<td>$ 442,190</td>
</tr>
</tbody>
</table>

| Shares used in per share calculation - diluted (GAAP) | 965,663 | 967,928 | 966,087 | 964,614 |
| Dilutive securities | 2,403 | 2,799 | 2,223 | 2,408 |
| Shares used in per share calculation - diluted (Non-GAAP) | 968,066 | 970,727 | 968,310 | 967,022 |

| Net income per share - diluted (GAAP) | $ 0.46 | $ 0.42 | $ 0.97 | $ 0.85 |
| Net income per share - diluted (Non-GAAP) | $ 0.49 | $ 0.46 | $ 1.03 | $ 0.92 |